Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6166 | SR 1664 |
| Antidiabetic agent; binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity. Does not inhibit Cdk5-dependent phosphorylation of Rb. Reduces fasting insulin levels and improves insulin sensitivity in a mouse model of diabetes. | |
| BCC6167 | Ocinaplon |
| Modulator of GABAA receptors. Displays modest selectivity for GABAA α1 receptors; displays partial agonist activity at α2-, α3- and α5-containing receptors. Exhibits anxiolytic activity. | |
| BCC6169 | TP 003 |
| Functionally selective GABAA receptor (α3 subtype) partial agonist. Exhibits affinity for the benzodiazepine binding site on human GABAA receptors. Potentiates the GABA (α3 subtype) response selectively with high efficacy. Produces anxiolytic-like effects in rodent behavioral models of anxiety. | |
| BCC6176 | SR 16584 |
| Selective α3β4 nAChR antagonist (IC50 = 10.2 μM). Selectively binds α3β4 over α4β2 and α7 subtypes (Ki values are 0.508, >100 and >100 μM, respectively). | |
| BCC6179 | TC-N 1752 |
| Selective blocker of human NaV1.7 channels (IC50 values are 0.17, 0.3, 0.4 and 1.1 μM at hNaV1.7, hNaV1.3, hNaV1.4 and hNaV1.5 respectively). Also inhibits tetrodotoxin-sensitive sodium channels. Displays analgesic efficacy in the formalin pain model. | |
| BCC6182 | SEN 12333 |
| α7 nicotinic acetylcholine receptor (nAChR) agonist (EC50 = 1.6 μM, Ki = 260 nM at rat α7 nAChRs). Also displays functional antagonism at histamine H3 receptors (IC50 = 103 nM) and weak agonist activity at human ganglionic α3 nAChRs (IC50 = 8.5 μM). Neuroprotective in a rodent model of quisqualic acid-induced cholinergic degeneration. Brain penetrant and orally bioavailable. | |
| BCC6184 | Fatostatin A |
| Inhibitor of sterol regulatory element binding protein (SREBP); impairs the activation of SREBP-1 and SREBP-2. Exhibits antiproliferative effects in DU 145 cells independently of IGF-1 signaling (IC50 = 0.1 μM); reverses hyperglycemia in diabetic (ob/ob) mice. Cell permeable. | |
| BCC6185 | 2-((1,1-Dioxidotetrahydrothiophen-3-yl)(methyl)amino)-2-oxoethyl 3-(3-nitrophenyl)acrylate |
| Inhibitor of Krüppel-like factor 5 (KLF5) transcription factor (IC50 = 2.3 μM). Selectively active against colon cancer cells in a panel of 60 different cancer cell lines. | |
